Interleukin-1β gene polymorphisms associated with hepatocellular carcinoma in hepatitis C virus infection

Hepatology

Volumn 37, Issue 1, 2003, Pages 65-71

  Wang, Yue ^a   Kato, Naoya ^a,c   Hoshida, Yujin ^a   Yoshida, Hideo ^a   Taniguchi, Hiroyoshi ^a   Goto, Tadashi ^a   Moriyama, Masaru ^a   Otsuka, Motoyuki ^a   Shiina, Shuichiro ^a   Shiratori, Yasushi ^a   Ito, Yoichi ^b   Omata, Masao ^a  

^a UNIVERSITY OF TOKYO   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

^c NONE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA FETOPROTEIN; INTERLEUKIN 1 RECEPTOR; INTERLEUKIN 1BETA; TUMOR NECROSIS FACTOR ALPHA; INTERLEUKIN 1;

ADULT; AGE; AGED; ARTICLE; CHRONIC HEPATITIS; CONTROLLED STUDY; DISEASE ASSOCIATION; DNA POLYMORPHISM; FEMALE; GENE LINKAGE DISEQUILIBRIUM; GENOTYPE; HAPLOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; POLYMERASE CHAIN REACTION; POLYMORPHIC LOCUS; PRIORITY JOURNAL; SEX DIFFERENCE; GENETIC POLYMORPHISM; GENETIC PREDISPOSITION; GENETICS; LIVER TUMOR; MIDDLE AGED; RISK FACTOR; VIROLOGY;

ADULT; AGED; CARCINOMA, HEPATOCELLULAR; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HEPATITIS C, CHRONIC; HUMANS; INTERLEUKIN-1; LIVER NEOPLASMS; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC; RISK FACTORS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0037207461     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1053/jhep.2003.50017     Document Type: Article

References (50)

1. World Health Organization 1998 Press releases. http://www.who.int/inf-pr-1998/en/pr98-36.html
2. Tong MJ, El-Farra NS, Reikes AR, Co RL. Clinical outcomes after transfusion-associated hepatitis C. N Engl J Med 1995;332:1463-1466.
3. Poynard T, Bedossa P, Opolon P for the OBSVIRC, METAVIR, CLINI-VIR, and DOSVIRC groups. Natural history of liver fibrosis progression in patients with chronic hepatitis C. Lancet 1997;349:825-832.
4. Saito I, Miyamura T, Ohbayashi A, Harada H, Katayama T, Kikuchi S, Watanabe Y, et al. Hepatitis C virus infection is associated with the development of hepatocellular carcinoma. Proc Natl Acad Sci U S A 1990;87: 6547-6549.
5. Shiratori Y, Shiina S, Imamura M, Kato N, Kanai F, Okudaira T, Teratani T, et al. Characteristic difference of hepatocellular carcinoma between hepatitis B and C viral infection in Japan. Hepatology 1995;22:1027-1033.
6. Takano S, Yokosuka O, Imazeki F, Tagawa M, Omata M. Incidence of hepatocellular carcinoma in chronic hepatitis B and C: A prospective study of 251 patients. Hepatology 1995;21:650-655.
7. Taylor-Roibinson SD, Foster GR, Arora S, Hargreaves S, Thomas HC. Increase in primary liver cancer in the UK, 1979-94. Lancet 1997;350:1142-1143.
8. Deuffic S, Poynard T, Buffat L, Valleron AJ. Trends in primary liver cancer. Lancet 1998;351:214-215.
9. El-Serag HB, Mason AC. Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med 1999;340:745-750.
10. Tarao K, Rino Y, Ohkawa S, Shimizu A, Tamai S, Miyakawa K, Aoki H, et al. Association between high serum alanine aminotransferase levels and more rapid development and higher rate of incidence of hepatocellular carcinoma in patients with hepatitis C virus-associated cirrhosis. Cancer 1999;86:589-595.
11. Yoshida H, Shiratori Y, Moriyama M, Arakawa Y, Ide T, Sata M, Inoue O, et al. for the IHIT study group. Interferon therapy reduces the risk for hepatocellular carcinoma: National surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan. Ann Intern Med 1999;131:174-181.
12. Koziel MJ. Cytokines in viral hepatitis. Semin Liver Dis 1999;19:157-169.
13. Losser MR, Payen D. Mechanisms of liver damage. Semin Liver Dis 1996;16:357-367.
14. Dinarello CA. Biologic basis for interleukin-1 in disease. Blood 1996;87:2095-2147.
15. Vassali P. The pathophysiology of tumor necrosis factors. Annu Rev Immunol 1992;10:411-452.
16. El-Omar EM. The importance of interleukin 1b in Helicobacter pylori associated disease. Gut 2001;48:743-747.
17. Tilg H, Wilmer A, Vogel W, Herold M, Nölchen B, Judmaier G, Huber C. Serum levels of cytokines in chronic liver diseases. Gastroenterology 1992;103:264-274.
18. Kishihara, Y, Hayashi J, Yoshimura E, Yamaji K, Nakashima K, Kashiwagi S. IL-1β and TNF-α produced by peripheral blood mononuclear cells before and during interferon therapy in patients with chronic hepatitis C. Dig Dis Sci 1996;41:315-321.
19. Bidwell JL, Keen LJ, Gallagher G, Kimberly R, Huizinga T, McDermott MF, Oksenberg J, et al. Cytokine Gene Polymorphism in Human Disease. On-line Databases. http://www.pam.bris.ac.uk/services/GAI/cytokine4.htm
20. El-Omar EM, Carrington M, Chow W-H, McColl, KEL, Bream JH, Young HA, Herrera J, et al. Interleukin-1 polymorphisms associated with increased risk of gastric cancer. Nature 2001;412:99.
21. El-Omar EM, Carrington M, Chow W-H, McColl, KEL, Bream JH, Young HA, Herrera J, et al. Interleukin-1 polymorphisms associated with increased risk of gastric cancer. Nature 2000;404:398-402.
22. *2) is associated with enhanced IL-1β production in vitro. Scand J Immunol 1998;47:195-198.
23. Mansfield JC, Holden H, Tarlow JK, KiGiovine F, McDowell TL, Wilson AG, Holdsworth CD, et al. Novel genetic association between ulcerative colitis and the anti-inflammatory cytokine interleukin-1 receptor antagonist. Gastroenterology 1994;106:637-642.
24. Herebach D, Alizadeh M, Dabadie A, Le Berre N, Colombel JF, Yaouanq J, Bretagne JF, et al. Significance of interleukin-1β and interleukin-1 receptor antagonist genetic polymorphism in inflammatory bowel diseases. Am J Gastroenterol 1997;92:1164-1169.
25. Blakemore AIF, Tarlow JK, Cork MJ, Gordon C, Emery P, Duff GW. IL-1 receptor antagonist gene polymorphism as a disease severity factor in systemic lupus erythematosus. Arthritis Rheum 1994;37:1380-1385.
26. Perrier S, Coussediere C, Dubost JJ, Albuisson E, Sauvezie B. IL-1 receptor antagonist (IL1RA) gene polymorphism in Sjögren's syndrome and rheumatoid arthritis. Clin Immunol Immunopathol 1998;87:309-313.
27. Wilson AG, Symons JA, McDowell TL, McDevitt HO, Duff GW. Effects of a polymorphism in the human tumor necrosis factor α promoter on transcriptional activation. Proc Natl Acad Sci U S A 1997;94:3195-3199.
28. Negoro K, Kinouchi Y, Hiwatashi N, Takahashi S, Takagi S, Satoh J, Shimosegawa T, et al. Crohn's disease is associated with novel polymorphisms in the 5′-flanking region of the tumor necrosis factor gene. Gastroenterology 1999;117:1062-1068.
29. Cookson S, Constantini PK, Clare M, Underhill JA, Bernal W, Czaja AJ, Donaldson PT. Frequency and nature of cytokine gene polymorphisms in type I autoimmnune hepatitis. Hepatology 1999;30:851-856.
30. Rosen HR, Lentz JJ, Rose SL, Rabkin J, Corless CL, Taylor K, Chou S. Donor polymorphism of tumor necrosis factor gene. Relationship with variable severity of hepatitis C recurrence after liver transplantation. Transplantation 1999;68:1898-1902.
31. Knight JC, Udalova I, Hill AVS, Greenwood BM, Peshu N, Marsh K, Kwiatkowski D. A polymorphism that affects OCT-1 binding to the TNF promoter region is associated with severe malaria. Nat Genet 1999;22:145-150.
32. Desmet VJ. Histopathology of chronic hepatitis. In: Liaw YF, ed. Chronic Hepatitis. Amsterdam: Elsevier, 1986:27-44.
33. Scheuer PJ, Ashrafzadeh P, Sherlock S, Brown D, Dusheiko GM. The pathology of hepatitis C. Hepatology 1992;15:567-571.
34. Togo G, Toda N, Kanai F, Kato N, Shiratori Y, Kishi K, Imazeki F, et al. A transforming growth factor β type II receptor gene mutation common in sporadic cecum cancer with microsatellite instability. Cancer Res 1996;56:5620-5623.
35. Hsieh FY, Bloch DA, Larsen MD. A simple method of size calculation for linear and logistic regression. Stat Med 1998;17:1623-1634.
36. Tsukuma H, Hiyama T, Tanaka S, Nakao M, Yabuuchi T, Kitamura T, Nakanishi K, et al. Risk factors for hepatocellular carcinoma among patients with chronic liver disease. N Engl J Med 1993;328:1797-1801.
37. Ikeda K, Saitoh S, Arase Y, Chayama K, Suzuki Y, Kobayashi M, Tsubota A, et al. Effect of interferon therapy on hepatocellular carcinogenesis in patients with chronic hepatitis type C: A long-term observation study of 1,643 patients using statistical bias correction with proportional hazard analysis. Hepatology 1999;29:1124-1130.
38. Shuto T, Hirohashi K, Ikebe T, Mikami S, Yamamoto T, Kubo S, Wakasa K, et al. Additional hepatocellular carcinomas undetectable before surgery. World J Surg 2000;24:1566-1569.
39. Takamatsu M, Yamauchi M, Maezawa Y, Saito S, Maeyama S, Uchikoshi T. Genetic polymorphisms of interleukin-1β in association with the development of alcoholic liver disease in Japanese patients. Am J Gastroenterol 2000;95:1305-1311.
40. Tian Z, Shen X, Feng H, Gao B. IL-1β attenuates IFN-αB-induced anti-viral activity and STAT1 activation in the liver: Involvement of protea-some-dependent pathway. J Immunol 2000;165:3959-3965.
41. Vautier G, Bomford AB, Portmann BC, Metivier E, Williams R, Ryder SD. P53 mutations in British patients with hepatocellular carcinoma: Clustering in genetic hemochromatosis. Gastroenterology 1999;117:154-160.
42. De la Coste A, Romagnolo B, Billuart P, Renard CA, Buendia MA, Soubrane O, Fabre M, et al. Somatic mutations of the beta-catenin gene are frequent in mouse and human hepatocellular carcinomas. Proc Natl Acad Sci U S A 1998;95:8847-8851.
43. Feitelson MA, Sun B, Tufan NLS, Liu J, Pan JB, Lian ZR. Genetic mechanisms of hepatocarcinogenesis. Oncogene 2002;21:2593-2604.
44. Laurent-Puig P, Legoix P, Bluteau O, Belghiti J, Franco D, Binot F, Monges G, et al. Genetic alterations associated with hepatocellular carcinomas define distinct pathways of hepatocarcinogenesis. Gastroenterology 2001;120:1763-1773.
45. Yeh SH, Chen PJ, Shau WY, Chen YW, Lee PH, Chen JT, Chen DS. Chromosomal allelic imbalance evolving from liver cirrhosis to hepatocellular carcinoma. Gastroenterology 2001;121:699-709.
46. Iwata N, Yamamoto H, Sasaki S, Itoh F, Suzuki H, Kikuchi T, Kaneto H, et al. Frequent hypermethylation of CpG islands and loss of expression of the 14-3-3 sigma gene in human hepatocellular carcinoma. Oncogene 2000;19:5298-5302.
47. Vogel A, Kneip S, Barut A, Ehmer U, Tukey RH, Manns MP, Strassburg CP. Genetic link of hepatocellular carcinoma with polymorphisms of the UDP-glucuronosyltransferase UGT1A7 gene. Gastroenterology 2001;121:1136-1144.
48. Lieber CS. Alcohol and the liver: 1994 Update. Gastroenterology 1994;106:1085-1105.
49. Bruno S, Silini E, Crosignani A, Borzio F, Leandro G, Bono F, Asti M, et al. Hepatitis C virus Genotypes and risk of hepatocellular carninoma in cirrhosis: A prospective study. Hepatology 1997;25:754-758.
50. Chen THH, Chen CJ, Yen MF, Lu SN, Sun CA, Huang GT, Yang PM, et al. Ultrasound screening and risk factors for death from hepatocellular carcinoma in a high risk group in Taiwan. Int J Cancer 2002;98:257-261.